CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) by Azurity is components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Approved for combination with a reduced-calorie diet, increased physical activity to reduce excess body weight, maintain weight reduction long term in adults with obesity and 1 more indications. First approved in 2014.
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
CONTRAVE is an oral extended-release tablet combining naltrexone (opioid antagonist) and bupropion (dopamine/norepinephrine reuptake inhibitor) approved in 2014 for chronic weight management. It works by targeting the hypothalamus (appetite regulation) and mesolimbic dopamine circuit (reward system), though the exact neurochemical mechanism driving weight loss remains incompletely understood. Indicated for use with reduced-calorie diet and increased physical activity in adults with obesity or overweight with comorbid conditions.
Product is at peak maturity with modest Part D utilization (1,707 claims in 2023), indicating a stable but niche market position with limited commercial expansion opportunities.
components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the…
Worked on CONTRAVE at Azurity? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCONTRAVE offers stable career positioning in a mature peak-phase product with established market presence, but limited growth trajectory and incoming generic competition in 8 years create urgency for portfolio transition planning. Roles focused on market access optimization, managed care negotiations, and brand defense against emerging obesity therapies offer the highest strategic value.